Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme

被引:20
|
作者
Masuyer, Geoffrey [1 ]
Douglas, Ross G. [2 ,3 ]
Sturrock, Edward D. [2 ,3 ]
Acharya, K. Ravi [1 ]
机构
[1] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England
[2] Univ Cape Town, Dept Integrat Biomed Sci, ZA-7935 Observatory, South Africa
[3] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7935 Observatory, South Africa
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
ASPARTYL-LYSYL-PROLINE; TERMINAL CATALYTIC DOMAIN; 2; ACTIVE-SITES; N-DOMAIN; CRYSTAL-STRUCTURE; KININASE-II; INHIBITOR; PEPTIDE; FIBROSIS; SPECIFICITY;
D O I
10.1038/srep13742
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Angiotensin-I converting enzyme (ACE) is a zinc dipeptidylcarboxypeptidase with two active domains and plays a key role in the regulation of blood pressure and electrolyte homeostasis, making it the principal target in the treatment of cardiovascular disease. More recently, the tetrapetide N-acetylSer- Asp-Lys-Pro (Ac-SDKP) has emerged as a potent antifibrotic agent and negative regulator of haematopoietic stem cell differentiation which is processed exclusively by ACE. Here we provide a detailed biochemical and structural basis for the domain preference of Ac-SDKP. The high resolution crystal structures of N-domain ACE in complex with the dipeptide products of Ac-SDKP cleavage were obtained and offered a template to model the mechanism of substrate recognition of the enzyme. A comprehensive kinetic study of Ac-SDKP and domain co-operation was performed and indicated domain interactions affecting processing of the tetrapeptide substrate. Our results further illustrate the molecular basis for N-domain selectivity and should help design novel ACE inhibitors and Ac-SDKP analogues that could be used in the treatment of fibrosis disorders.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme
    Geoffrey Masuyer
    Ross G. Douglas
    Edward D. Sturrock
    K. Ravi Acharya
    Scientific Reports, 5
  • [2] Ac-SDKP, a marker of the angiotensin-converting enzyme activity?
    Mimouni, S
    Raffaitin, C
    Corcuff, JB
    ANNALES DE BIOLOGIE CLINIQUE, 2006, 64 (01) : 11 - 16
  • [3] Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension
    Rasoul, S
    Carretero, OA
    Peng, HM
    Cavasin, MA
    Zhuo, JL
    Sanchez-Mendoza, A
    Brigstock, DR
    Rhaleb, NE
    JOURNAL OF HYPERTENSION, 2004, 22 (03) : 593 - 603
  • [4] Ac-SDKP mediates the antifibrotic effect of angiotensin-converting enzyme inhibitor in hypertension
    Rhaleb, NE
    Carretero, OA
    Peng, HM
    CIRCULATION, 2004, 110 (17) : 101 - 101
  • [5] RESISTANCE OF ANGIOTENSIN-I CONVERTING ENZYME TO HYDROLYSIS BY SERINE PROTEASES
    OZA, NB
    LANZILLO, JJ
    RYAN, JW
    FANBURG, BL
    BIOCHEMICAL PHARMACOLOGY, 1982, 31 (07) : 1443 - 1445
  • [6] ANGIOTENSIN-I CONVERTING ENZYME
    ERDOS, EG
    CIRCULATION RESEARCH, 1975, 36 (02) : 247 - 255
  • [7] ANGIOTENSIN-I CONVERTING ENZYME
    ERDOS, EG
    FEDERATION PROCEEDINGS, 1977, 36 (05) : 1760 - 1765
  • [8] Is plasma Ac-SDKP level a reliable marker of chronic angiotensin-converting enzyme inhibition in hypertensive patients?
    Le Meur, Y
    Aldigier, JC
    Praloran, V
    HYPERTENSION, 1998, 31 (05) : 1201 - 1201
  • [9] ANGIOTENSIN-I CONVERTING ENZYME AND KININASE
    UEDA, E
    AKUTSU, H
    ITO, T
    KOKUBU, T
    JAPANESE CIRCULATION JOURNAL, 1972, 36 (06): : 583 - &
  • [10] Antifibrotic effect of angiotensin-converting enzyme inhibitor is mediated by Ac-SDKP in aldosterone-salt-induced hypertension
    Peng, HM
    Carretero, OA
    Liao, TD
    Peterson, E
    Rhaleb, NE
    HYPERTENSION, 2005, 46 (04) : 870 - 870